Damora Therapeutics is trading 5.4% higher at $29.86 as a broader market rebound lifts equities despite a lack of company-specific catalysts.
- The upward move is largely attributed to risk-on sentiment following improved inflation data and strong earnings reports from large-cap technology companies.
- The stock is outperforming the healthcare sector, which has shown general weakness during this morning's session.
- There have been no fresh earnings, FDA regulatory updates, or major news events reported specifically for the company today.